ampicillin/sulbactam / Generic mfg. - LARVOL DELTA

Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators against Acinetobacter baumannii-calcoaceticus complex strains isolated from respiratory and bloodstream sources: results from ACNBio study. (PubMed, Antimicrob Agents Chemother) - "Minocycline susceptibility was <50%, while tigecycline and eravacycline MIC50/90 were 1/2 and 0.5/1 µg/mL, respectively. Susceptibility rates of clinically utilized antimicrobials against a US collection of ABC isolates ranged from 23% to 97%, with meropenem displaying the lowest rate and sulbactam-durlobactam demonstrating the highest overall rate. Sulbactam-durlobactam activity was preserved against sulbactam, carbapenem, and cefiderocol non-susceptible isolates among respiratory tract and bloodstream isolates."

Journal • Critical care • Infectious Disease

Complex Hepatic Abscess in a Child Following Esophageal Procedures: Clinical Insights and Management. (PubMed, Cureus) - "The patient initially received ceftriaxone and metronidazole, showing improvement, but experienced fever recurrence upon switching to ampicillin/sulbactam, necessitating a return to the original antibiotic regimen. When infectious complications do occur, both antibiotic management and source control are necessary for definitive treatment. Further research is needed to establish guidelines for prophylactic measures in similar clinical scenarios."

Journal • Anorexia • Hepatology • Infectious Disease • Pain • Pediatrics

Factors Influencing Oronasal Fistula Formation After Cleft Palatoplasty: Insights from 10-Years of Surgical Outcomes (PSTM 2025) - "Of these, 60 received preoperative ampicillin-sulbactam, with five developing fistulas (8.33%); 17 received cefazolin with seven developing fistulas (41.18%); three received clindamycin, resulting in one fistula (33.3%). This study identifies factors contributing to fistula development at our institution. The use of preoperative cefazolin demonstrated higher fistula rates, suggesting that antibiotics with better oral flora coverage may be a factor in reducing the risk of fistula formation. This suggests the need for reevaluation of SCIP protocol antibiotic choices, which could influence plastic surgery preoperative antibiotic guidelines."

Infectious Disease

Characterization of bla NDM-5-carrying plasmids in two clinical Salmonella isolates from Jiaxing city, China. (PubMed, Front Microbiol) - "Both isolates were multidrug resistant, with insusceptibility to ampicillin, ampicillin/sulbactam, amoxicillin/clavulanic acid, cefuroxime, ceftiofur, cefazolin, cefoxitin, cefotaxime, ceftazidime, cefepime, ceftazidime/avibactam, meropenem, imipenem, ertapenem, tetracycline, gentamicin, trimethoprim/sulfamethoxazole, florfenicol, chloramphenicol, ciprofloxacin, colistin, and polymixin B. The bla NDM-5-carrying plasmids in 2023JX045 and 2024-406 were named p23045-NDM5 and p2024406-NDM5, respectively, with both belonging to the incompatibility (Inc)HI2/IncHI2A group and sequence type ST3. IS26-flanked composite transposons appeared to play an important role in the formation of this region. The dissemination of blaNDM in Salmonella isolates and the complexity of the bla NDM-5 region highlight the urgent need to monitor carbapenem-resistant S. enterica."

Journal • Infectious Disease

The effectiveness and safety between colistin-based and high-dose ampicillin/sulbactam-based combination antibiotic therapy for hospital-acquired pneumonia caused by Carbapenem-resistant Acinetobacter baumannii pneumonia (ERS 2025) - No abstract available

Clinical • Infectious Disease • Pneumonia • Respiratory Diseases

A new approach to treat carbapenem resistant Acinetobacter baumannii (CRAB) bacteremia using sulbactam-avibactam combination: A case report. (PubMed, IDCases) - "Only a few therapeutic options are available, with conflicting data for their meaningful clinical outcomes. Here, we report a case of 83-year-old female CRAB bacteremia that was successfully treated with ceftazidime-avibactam and ampicillin-sulbactam combination after failing guidelines directed therapy."

Journal • Infectious Disease

Multidisciplinary Management of Congenital Subglottic Stenosis in the Setting of Cystic Fibrosis (AAO-HNSF 2025) - "His postop course was complicated by increased peak inspiratory pressures on mechanical ventilation requiring frequent treatments, and tracheitis with H. influenzae and N. meningitidis treated with IV cefepime and ampicillin-sulbactam. This case emphasizes the unified airway theory and need for a broad differential of airway diagnoses in patients with CF who require repeated hospital admissions, unexplained O2 requirement, and intubation. A multidisciplinary approach is critical in the management of these complex airway patients."

Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Inflammation • Influenza • Respiratory Diseases

Chronic Salmonella Lymphadenitis in a Diabetic Patient (AAO-HNSF 2025) - "The patient received ampicillin-sulbactam, followed by piperacillin-tazobactam and linezolid, eventually ceftriaxone, and finally outpatient trimethoprim-sulfamethoxazole. Although initially concerning for malignancy, this case of cervical lymphadenopathy with abscess formation was found to be a chronic Salmonella infection of unknown source. Management required multidisciplinary care and highlighted the vigilance required in addressing rare infections in diabetic patients."

Clinical • Cardiovascular • Dermatology • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hypertension • Infectious Disease • Metabolic Disorders • Oncology • Pain

Peritonsillar abscess in children: A retrospective analysis on surgical and antimicrobial approaches. (PubMed, PLoS One) - "No relevant differences were found with regard to the complication rate between UTE und BTE in pediatric patients. Broad-spectrum antibiotics were used in accordance with the detected microbiological flora. Since 2019, calculated antibiotic therapy with Ampicillin-Sulbactam has been the treatment of choice for pediatric PTA."

Journal • Retrospective data • Infectious Disease • Otorhinolaryngology • Pediatrics

Delayed diagnosis of pulmonary tuberculosis with pleuritis due to ampicillin/sulbactam: A case report. (PubMed, World J Clin Cases) - "There are cases of TB wherein temporary improvement apparently could be shown through treatment with antimicrobial agents other than anti-TB drugs, necessitating careful evaluation in atypical cases of bacterial pneumonia."

Journal • Cardiovascular • Diabetes • Endocrine Disorders • Hypertension • Infectious Disease • Inflammation • Metabolic Disorders • Pain • Pneumonia • Pulmonary Disease • Respiratory Diseases • Tuberculosis

A Case of Transverse Myelitis With an Intrathecal Pump: A Case Report. (PubMed, Pain Med Case Rep) - "This case calls for early and prompt diagnosis and management of postimplant complications of an ITP."

Journal • Back Pain • CNS Disorders • Musculoskeletal Pain • Pain • Urinary Incontinence • Urology

Efficacy of cefoperazone-sulbactam as a component of combination therapy for carbapenem-resistant Acinetobacter baumannii bloodstream infection in intensive care units: a multicenter retrospective propensity score-matched study. (PubMed, BMC Infect Dis) - "As an alternative to ampicillin-sulbactam, cefoperazone-sulbactam could be considered as components of combination therapy for critically ill patients with CRAB BSI."

Journal • Retrospective data • Critical care • Infectious Disease • CRP

Underdosed and Underappreciated: Why Japanese Community-Acquired Pneumonia Outcomes With Ampicillin-Sulbactam May Not Translate Globally. (PubMed, Open Forum Infect Dis) - No abstract available

Journal • Infectious Disease • Pneumonia • Respiratory Diseases

OXA-carbapenemases and mutations within PBPs in ST2 carbapenem-resistant A. baumannii: evaluating the efficacy of cefiderocol and ampicillin-sulbactam combination therapy. (PubMed, J Glob Antimicrob Resist) - "The four clinical cases described in this study represent an important example of efficacy and good practice of FDC plus AMP/SUL combination in the treatment of critical patients suffering from CRAB infections."

Journal • Infectious Disease

Has the COVID-19 pandemic affected Vulvovaginitis in Prepuberty and Adolescent Females in China? A retrospective study of 4 644 cases during 2018-2021. (PubMed, J Pediatr Adolesc Gynecol) - "Our findings provide evidence-based guidance for appropriate antibiotic use and facilitate the optimization of therapeutic strategies and lifestyle recommendations for prepubertal and adolescent girls with VV."

Journal • Retrospective data • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Vaginitis

Genomic Diversity of the tet(X)-Positive Myroides Species. (PubMed, Microorganisms) - "All of them were MDR to tetracycline, ceftazidime, gentamicin, amikacin, colistin, ciprofloxacin, gatifloxacin, and trimethoprim-sulfamethoxazole, with elevated minimum inhibitory concentrations (MICs) for tigecycline, florfenicol, and macrolides, but exhibited susceptibility to meropenem (100%), ampicillin-sulbactam (66.7%), and cefotaxime (33.3%). The phylogenetic analysis highlighted interspecies transmission risks, with ISCR2-mediated transposons of tet(X6) and estT-2 across Myroides, Riemerella, Empedobacter, Providencia, Acinetobacter, and Proteus species. These findings illuminate the genomic diversity driving antibiotic resistance in understudied bacterial taxa, with implications for global One Health strategies."

Journal • Infectious Disease

Salvage Therapy Against Infections of MDR Acinetobacter baumannii Achieved by Synergistic Effect of Colistin-Containing Therapies-Preliminary Study. (PubMed, Microorganisms) - "In this study, six antibiotics were chosen to combine with colistin: amikacin, gentamicin, ampicillin/sulbactam, tigecycline, imipenem, and meropenem. Additive interactions have been shown in colistin combination with carbapenems, aminoglycosides, and tigecycline. The results prove the synergistic effect of the tested antibiotics, which may be helpful in the selection of potentially effective multi-drug therapies and their application in clinical practice, which may involve reducing the doses of colistin in therapy and its toxicity."

Journal • Infectious Disease

The Actual Clinical Situation Ruthlessly Exposes the Challenge of Rational Care for Nosocomial and Community-Acquired Infections and Requires Even More Efforts for Satisfactory Antibiotic Stewardship. (PubMed, Antibiotics (Basel)) - "Within the sub-cohort of ineffectively treated patients, i.e., with resistance to the antibiotic, mortality increases on average, but with ampicillin/sulbactam as a striking exception...The time series associated with the various antibiotics show pairwise time lag correlations, which indicates the existence of retardedly mediated cross-resistance. We conclude with an outlook on upcoming further analyses and a draft action plan on how to control and harness the complex dynamics observed by means of successful, informed, and intelligent antibiotic stewardship."

Journal • Critical care • Infectious Disease

Activity of β-Lactamase Inhibitor Combinations Against Enterobacterales Isolated from Patients with Intra-Abdominal Infection from United States Medical Centres (2019-2023). (PubMed, Antibiotics (Basel)) - "Only 51.6% of Enterobacterales were susceptible to ampicillin-sulbactam. Aztreonam-avibactam, ceftazidime-avibactam, and meropenem-vaborbactam exhibited almost complete activity (99.9% susceptibility) against Enterobacterales causing IAI in US hospitals. In contrast, piperacillin-tazobactam exhibited limited activity against these organisms, especially those with a MDR phenotype."

Journal • Infectious Disease • Pneumonia

Multicenter Evaluation of VITEK® REVEAL™ AST System vs. Standard BD Phoenix™ for Antimicrobial Susceptibility Testing of Gram-Negative Bacteria from Positive Blood Cultures (ASM Microbe 2025) - "We observed 100% CA for amikacin, amoxicillin/clavulanate, ertapenem, meropenem, meropenem/vaborbactam, and trimethoprim/sulfamethoxazole, and the remaining drugs demonstrated CA>90% except for ampicillin/sulbactam (89%). Depending on the drug/bug combination, the median TTR for VITEK® REVEAL™ results was 6.5 h (ranging between 3-8 h), while BD Phoenix™ displayed average TTR results of 32-42 h (including subculturing of 18-24 h).Our study shows that the VITEK® REVEAL™ AST system had acceptable CA against the BD Phoenix™ system for all tested antimicrobials except ampicillin/sulbactam. The VITEK® REVEAL™ average TTR was more than 20 h shorter than BD Phoenix™'s average TTR, allowing for faster assessment of optimal antimicrobial therapy."

Gram negative • Infectious Disease • Pneumonia

Evaluation of a Fast vs. Conventional System for Antimicrobial Susceptibility Testing of Gram-Negative Bacteria from Positive Blood Cultures (ASM Microbe 2025) - "We observed 100% CA for amikacin, ceftazidime/avibactam, ertapenem, meropenem, meropenem/vaborbactam, and trimethoprim/sulfamethoxazole. The VITEK® REVEAL™ AST system displayed acceptable CA for all antimicrobials tested except for ampicillin/sulbactam. The VITEK® REVEAL™ average TTR was 20-28 h shorter than MicroScan™'s, allowing for faster assessment of optimal antimicrobial therapy."

Gram negative • Infectious Disease • Pneumonia • Septic Shock

Evaluation of the ASTar® System for Rapid Susceptibility Testing Directly from Positive Blood Cultures from Oncology Patients with Bloodstream Infections (ASM Microbe 2025) - "The ASTar® panel was performed according to manufacturer's instructions and organisms were tested across 18 antimicrobials: amikacin, ampicillin, ampicillin/sulbactam, aztreonam, cefazolin, cefepime, ceftazidime, cefuroxime, ceftazidime/avibactam, ciprofloxacin, gentamicin, levofloxacin, meropenem, meropenem/vaborbactam, piperacillin/tazobactam, tobramycin, tigecyline, and trimethoprim/sulfamethoxazole. The ASTar® system yields reliable AST results with an overall CA of 94% and 99% EA. The ASTar® system combined with direct from positive blood rapid identification can help in the optimization of early antimicrobial therapy in patients with bloodstream infections."

Infectious Disease • Oncology • Pneumonia • Septic Shock

Antibiotic-Resistant Acinetobacter baumannii in Burn Wounds of Intensive Care Unit Admitted Patients: A Single-Centered, Cross-Sectional Study (ASM Microbe 2025) - "The lowest resistance against the antibiotics was demonstrated by the tetracycline group with Tetracycline (58.57%) and Doxycycline (38.58%). However, all isolates exhibited complete 100% resistance to both Ceftazidime and Ampicillin-sulbactam. Above 80% to 90% resistance was observed for all the other antibiotics tested, including Amikacin, Gentamicin, Cefepime, Levofloxacin, Piperacillin-tazobactam and Imipenem...The carbapenemase gene blaNDM-1 was detected in 45.5% of isolates, while blaVIM was absent. The high prevalence of MDR and XDR A. baumannii in hospital settings poses critical challenges in treatment management which is made further complicated by the high prevalence of ESBL and carbapenemase genes, particularly blaCTX-M and blaNDM-1 which underscores the complex resistance mechanisms in A. baumannii, demanding urgent infection control measures."

Clinical • Observational data • Critical care • Infectious Disease

Performance of a System for Direct Rapid Antimicrobial Susceptibility Testing from Blood Culture (ASM Microbe 2025) - "All antibiotics individually achieved >90% CA with the exception of ampicillin-sulbactam and cefazolin. The average run time for ASTar was 6.25 hours. These findings demonstrate that the Q-linea ASTar system delivers comparable results to traditional methods and performs within established laboratory standards, offering a valuable tool for optimizing antimicrobial therapy in BSIs."

Infectious Disease • Septic Shock

Performance of direct-from-blood-culture disk diffusion antibiotic susceptibility testing and its impact on antibiotic adjustment in bloodstream infections at a Malaysian tertiary center. (PubMed, Microbiol Spectr) - "The dAST achieved CA above 90% for Staphylococcus aureus with cefoxitin (98.5%), Pseudomonas aeruginosa with ceftazidime (100%), and Acinetobacter baumannii with ampicillin/sulbactam (100%). For Enterobacterales, most combinations were above 90%, including ampicillin (95.1%), ceftriaxone (95.7%), and meropenem (95.7%), though those of the aminopenicillin/inhibitor combinations were above 80%...This study from Malaysia adds insights into the performance of dAST and the potential to apply it in similar resource-limited settings from the same region. Furthermore, assessing the dAST's influence on antibiotic prescribing identifies the gap in implementation to guide areas of improvement for optimizing clinical utility."

Journal • Infectious Disease